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Vascular endothelial cells produce considerable amounts of matrix metalloproteinases 
(MMPs), including MMP-2, MMP-9 and membrane type 1 (MT1)-MMP. However, little 
is known about the regulatory mechanisms of these protease activities exhibited during 
vascular development. A glycosylphosphatidylinositol (GPI)-anchored glycoprotein, 
reversion-inducing cysteine-rich protein with Kazal motifs (RECK), has been shown to 
attenuate MMP-2 maturation by directly interacting with MT1-MMP. Here, we show that 
an angiogenic factor angiopoietin-1 induces RECK expression in human umbilical vein 
endothelial cells (HUVECs), and RECK depletion in these cells results in defective 
vascular tube formation and cellular senescence. We further observed that RECK 
depletion downregulates β1-integrin activation, which was associated with decreased 
autophosphorylation of focal adhesion kinase (FAK) and increased expression of a 
cyclin-dependent kinase (CDK) inhibitor p21CIP1. In agreement, significant 
downregulation of β1-integrin activity was observed in vascular endothelial cells in Reck-
/- mouse embryos. In HUVECs, specific inhibition of MMP-2 significantly antagonized 
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the effect of RECK depletion on β1-integrin signaling, cell proliferation and tube 
elongation. Furthermore, we observed that hyper-vascular tumor-derived cell lines can 
induce high RECK expression in convoluted vascular endothelial cells, and this in turn 
supports tumor growth. Targeting RECK specifically in tumor-associated vascular 
endothelial cells resulted in tumor regression. Therefore, we propose that RECK in tumor 
vascular endothelial cells can be an interesting target of cancer treatment via abortion of 





MMPs are Ca++ and Zn++-dependent endopeptidases that play crucial roles in the 
degradation of various extracellular matrix (ECM) components (1). In addition, recent 
studies have demonstrated that these enzymes exert unique biological functions by acting 
on various important modulators of cellular functions (2,3). During tumor propagation, 
not only tumor cells but also stromal cells, including vascular endothelial cells, produce 
considerable amounts of MMPs (4). In particular, during angiogenesis engaged by 
endothelial cells, MMPs play both positive and negative roles (5). The pro-angiogenic 
functions of MMPs include degradation of ECM components, which facilitates the 
invasion and migration of endothelial cells, cleavage of endothelial cell-cell adhesion 
mediated by cadherins, generation of cryptic integrin-binding sites from ECM 
components, and enhancement of the bioavailability of various growth factors such as 
vascular endothelial growth factor (VEGF), transforming growth factor β (TGFβ) and 
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connective tissue growth factor (CTGF) (5). On the other hand, the anti-angiogenic 
functions of MMPs include ectodomain shedding of receptors for growth factors such as 
fibroblast growth factor receptor 1 (FGFR1) and urokinase-type plasminogen activator 
receptor (uPAR), resulting in the inhibition of growth signals generated from these 
receptors (5). Other anti-angiogenic functions of MMPs include generation of cryptic 
angiogenesis inhibitors from plasminogen or collagens, such as angiostatin, endostatin, 
tumstatin, arrestin or canstatin; all of these are supposed to exert their anti-angiogenic 
functions by interacting with various forms of integrins including α5β1, αvβ3, α1β1 and 
α3β1 (5,6). Moreover, soluble hemopexin (PEX) domain derived from degraded MMP-2 
blocks the binding of intact MMP-2 to integrin αvβ3 (7). These findings suggest that the 
anti-angiogenic functions of MMPs profoundly involve integrin signaling.  
 
Integrins principally serve as adhesion receptors for ECM components and provide the 
central system to transduce biochemical signals from outside of the cells (6). Ligand 
occupancy and the resultant clustering of integrin receptors induce autophosphorylation 
of FAK, which evokes cellular actions (proliferation, migration, spreading or apoptosis) 
that enable cells to adjust to changes in the extracellular environment (8).   
 
The RECK gene has been identified as a negative transcriptional target of molecules, 
including multiple retroviral oncogenes (9), Epstein-Barr virus latent membrane protein 1 
(LMP1) (10), histone deacetylase (HDAC) (11) and oncogenic micro-RNA miR-21 
(12~14). The product of this gene can directly bind to a series of metalloendopeptidases, 
including MMP-9 (9), MMP-2 (15), MT1-MMP, CD13/APN (16) and ADAM10 (17), 
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and attenuate their proteolytic activity competitively in most of cases. Two 
metalloprotease-substrate-like domains recently discovered in RECK may provide a 
structural basis for its biochemical actions (Takegami and Takahashi, in preparation for 
publication). Yet, the most discrete structural feature of RECK compared to known 
primary tissue metalloprotease inhibitors, such as tissue inhibitors of metalloproteinases 
(TIMPs) and α2-macroglobulins (18), is that RECK is covalently anchored to the plasma 
membrane surface via glycosylphosphatidylinositol (GPI)-anchors. Because of this 
structural feature, RECK controls metalloendopeptidase activities in highly limited 
distance from the membrane surface (perimembrane area), and moreover, it exerts unique 
functions by interacting with membrane-tethered metalloendopeptidases. Indeed, 
molecular interaction between RECK and MT1-MMP enables MT1-MMP to translocate 
to the lipid raft fraction, which consequently changes the route of MT1-MMP endocytosis 
to one that is specific to that of GPI-anchored proteins; this results in a shorter half life of 
MT1-MMP (16). Furthermore, RECK was found to stabilize the interaction between 
membrane-bound Notch ligands and Notch receptors by protecting Notch ligands from 
ADAM10-mediated ectodomain shedding, which critically contributes to the 
maintenance of the self-renewal property of neural stem cells (17).  
 
We recently observed that treatment with an angiogenic factor, namely, angiopoietin-1, or 
coculture with hyper-vascular tumor-derived cells markedly induced RECK expression in 
human umbilical vein endothelial cells (HUVECs), which indicates that RECK may 
possess pro-angiogenic function. Indeed, severe developmental defects in the vascular 
network were observed in the previous analysis of Reck-/- embryos (15). No such vascular 
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phenotypes were observed in mice deficient in known soluble MMP inhibitors (18). We 
further examined Reck-/- mice, and identified significant developmental defects in 
vascular endothelial cells. Although the vascular phenotype appearing in Reck-/- embryos 
can be attributed not only to the defects in endothelial cells but also to those in smooth 
muscle cells, pericytes and the surrounding stromal cells, in this study, we focused on the 
role of RECK in the development of vascular endothelial cells under physiological and 
pathological (tumor angiogenesis) conditions mainly by employing RNA interference 
techniques.  
 
Materials and Methods 
 
Cell culture and transfection. The human umbilical vein endothelial cells (HUVECs; 
CC2517, CAMBREX) were maintained in EBM-2 (growth factor-free) or EGM-2 
(supplemented with endothelial cell growth factors) bullet kit (CC-3162, CAMBREX) 
and used between passage 3 to 6. Tumor cells were cultured in DMEM supplemented 
with 10% FCS. Transfection of HT1080 cells was described (16).  
 
Antibody. The following mouse or rat primary antibodies were used: anti-RECK (9), 
anti-α-tubulin (CP06, Calbiochem), anti-MMP-2 (F-68, Biotechnology Products), anti-
BrdU (MAB4072, Chemicon), anti-active β1-integrin (9EG7, Chemicon), anti-β1- 
integrin (610467, BD), anti-phosphorylated FAK (FAKpY397) (611722, BD), anti-FAK 
(sc-557, Santa Cruz), anti-p21 (556430, BD), anti-CD31 (01951A, Pharmingen) (for 
nude mouse assay), anti-CD31 (ab28364, Abcam) (for human tumor), and anti-human 
Miki et al., MCR-09-0351R (second revise) 
 7
CD34 (hCD34) (CBL496, Chemicon) antibodies. As secondary antibodies, we used anti-
mouse IgG PE (550083, BD), anti-mouse IgG Alexa fluor 555 (A21424, Molecular 
Probes), anti-rat IgG APC (734820, Cell Lab), anti-mouse IgG Texas red (T862, 
Molecular Probes) and anti-rabbit IgG Alexa fluor 488 (Molecular Probes, A11034) 
antibodies. For stimulating β1-integrin activation, we used mouse anti-β1 integrin 
monoclonal antibody (P4G11, Chemicon)(19).  
 
Immunoblotting. Immunoblotting was performed as described previously (16). 
 
Mice. Reck+/- mice (15) were crossed with C57BL/6 Cr Slc TgN(act-EGFP)OsbC14-
Y01-FM131 (20), and resultant progenies were intercrossed to generate Reck-/- embryos 
transmitting enhanced green fluorescent protein (EGFP) gene.  
 
RNA interference. The siRNAs specifically targeting human RECK (siRNA1: 29149; 
siRNA2: 29155) and EGFP (4626), and negative control (4611G) were purchased from 
Ambion, and those targeting MMP-2 were purchased from Invitrogen (siRNA1: 1178208, 
siRNA2: 1178210). 1 x 105 HUVECs were transfected with 50 μM siRNA using 
Lipofectamine2000 (Invitrogen). 
 
MMP assay. The synthetic peptide Mca-Lys-Pro-Leu-Gly-DPA-Ala-Arg-NH2 (5 μM) was 
mixed with culture supernatants from HUVECs transfected with siRNA, and incubated at 
37°C for 30 min. Cleavage was measured as described previously (16). For the detection 
of MMP-2, culture supernatant was filtered through 0.45 μm ultrafiltration membrane 
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and incubated with gelatin sepharose 4B (GE healthcare) at 4 oC. Proteins bound to the 
beads were analyzed by immunoblotting using antibody to MMP-2. Signal intensity was 
measured using LAS3000 chemiluminescence imaging system (Fuji, Japan).  
 
2D and 3D vascular formation assay. For 2D culture, 4 x 104 HUVECs transduced with 
siRNA were grown on growth factor-reduced Matrigel (354230, BD)-coated wells and 
incubated at 37 °C for 48 h. For 3D culture, type I collagen (Cellmatrix type I-A, Nitta 
gelatin) solution was mixed on ice with 10 x Modified Eagle’s Medium, and then with 1 
x 106 cells/ml. The mixture was allowed to solidify for 30 min at 37°C, and incubated 
with EGM-2 bullet kit supplemented with 50 ng/ml phorbol 12-myristate 13-acetate 
(PMA) for 5 days. 
 
RT-PCR. RNA was extracted using Trizol (15596-026, Invitrogen) and reverse 
transcribed using TaKaRa RNA PCR kit (RR019A, TaKaRa). PCR was performed with 
specific primer sets: RECK (30 cycles), sense: 5'-ACTCCCTCCTCCTTCCCCTCAGC-
3'; antisense: 5'-ATTTAATCAGCTTGCTTTTGCAT-3', GAPDH (28 cycles), sense: 5'-
ACCACAGTCCATGCCATCAC-3'; antisense: 5'-TCCACCACCCTGTTGCTGTA-3', 
β1-integrin, sense: 5'-TTATCCTTCTATTGCTCACCTTGTC-3'; antisense: 5'-
ATAACCTCTACTTCCTCCGTAAAGC-3'.  
 
Proliferation assay. HUVECs were grown on 96-well type plates (2 x 103 cells/well). 
After siRNA transfection, the cell numbers were subsequently quantified using Cell 
Count reagent SF (07553-15, Nacalai tesque, Japan). 
Miki et al., MCR-09-0351R (second revise) 
 9
 
BrdU uptake and cell cycle. Cultured cells were incubated with 3 μg/ml of 5-bromo-2'-
deoxyuridine (BrdU) for 90 min, trypsinized, and fixed with 70% ethanol. E9.5 embryos 
were labeled in utero for 2 h by a single pulse of BrdU (3 mg). Samples were reacted 
with anti-BrdU and then with anti-mouse IgG PE antibody, and subjected to flow 
cytometry-assisted cell sorting (FACS) analysis. For measuring propidium iodide (PI) 
incorporation, cells were fixed with 4% paraformadldehyde (PFA) in phosphate buffered 
saline (PBS) and suspended in PBS with 50 µg/mL PI and 100 U/mL Ribonuclease A. At 
least 10,000 events were acquired, 
 
SA-β gal assay. Senescence-associated (SA)-β galactosidase (β-gal) activity in cells was 
detected as described previously (21). 
 
FACS analysis. HUVECs were trypsinized, fixed with 4% PFA, suspended in PBS with 
0.5% bovine serum albumin (BSA), and stained with anti-β1-integrin antibodies (active 
form: 9EG7; total β1 integrin: P4G11) and secondary with anti-rat IgG-APC or anti-
mouse IgG-PE, respectively. Data were collected using FACS Aria (BD Biosciences). 
 
Immunohistochemistry. The specimens were fixed with 1% PFA, embedded in optimal 
cutting temperature (OCT) compound, and stained as described previously (17). 
 
Luciferase assay. 4 x 105 HUVECs were plated onto 60 mm dishes, and transfected with 
mouse Reck promoter luciferase reporter pGL3-4110-luc (22) and pCMV-β-gal 
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expression vector (21). Twenty-four hours after transfection, cells were trypsinized, 
mixed with 4 x 105 tumor cells, and cultured for 24 h. Luciferase and β-gal activities in 
cells were measured as described (23). β-gal activity was used to normalize luciferase 
activity in each transfection.  
 
Human tumors. Biopsy samples of adrenal mass were collected from two patients with 
neuroblastoma who had been treated at Kyoto University Hospital, and analyzed 
according to the guideline of Kyoto University Graduate School of Medicine. Informed 
consent was obtained from the guardians of patients. 
 
SCID mouse model of tumor angiogenesis. Porous poly-L-lactic acid (PLLA) (Sigma) 
scaffolds were prepared as described (24). 5 x 105 siRNA-transfected HUVECs and 
HT1080 cells each were mixed with Matrigel, loaded into scaffolds, and implanted 
subcutaneously into five-week-old female severe combined immunodeficiency (SCID) 
mice (CLEA, Osaka, JAPAN). Three weeks after transplantation, recovered scaffolds 




Angiopoietin-1 upregulates RECK in vascular endothelial cells. To address whether 
RECK is involved in the development of vascular endothelial cells, we first examined the 
effects of various angiogenic factors on the transcriptional regulation of RECK in 
HUVECs cultured in EBM-2 (growth factor-free culture medium). This study revealed 
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that RECK expression in HUVECs was induced by angiopoietin-1, but not by vascular 
endothelial growth factor (VEGF), fibroblast growth factor (FGF) or epidermal growth 
factor (EGF) (Fig. 1A), suggesting that RECK expression is regulated in vascular 
endothelial cells by a specific angiogenic factor.  
 
Abnormal vascular endothelial development in Reck-null embryos. A previous study 
revealed that Reck-/- embryos exhibited abnormal branching of vasculatures, and 
overexpression of RECK in tumor cells modified tumor angiogenesis (15). We therefore 
speculated that RECK could be implicated in both physiological and pathological 
angiogenesis. Additional introduction of the genetic background carrying enhanced green 
fluorescent protein (EGFP) transgene into Reck-/- embryos enabled us to observe the 
presence of significant developmental defects in vascular endothelial cells, namely, 
abnormal alignment and detachment from the subendothelial layer (Fig. 1B); these were 
not aware in the previous study without introducing EGFP background (15). We observed 
such obvious morphological disorders of vascular alignment in 4 out of 5 Reck-/-; EGFP 
E10.0 embryos by carefully observing vasculatures in multiple slices of thin paraffin 
sections under fluorescence microscope, but never in 5 control embryos. These findings 
prompted us to examine the function of RECK specifically in vascular endothelial cells.  
 
RECK depletion affects tube formation by HUVECs. To directly assess the role of 
RECK in angiogenesis, we performed siRNA-directed depletion of RECK in HUVECs 
cultured in EGM-2 (culture medium supplemented with growth factors), which resulted 
in more than 95% reduction in RECK expression at 48 h after transduction (Fig. 1C, left). 
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This treatment increased the net metalloendopeptidase activity detected in the culture 
supernatant by 2~3 fold compared to that in control supernatant (Fig. 1C, middle). We 
also observed increased level of active form MMP-2 in RECK-depleted HUVECs (Fig. 
1C, right). HUVECs transduced with control siRNA expressed RECK at 6 h after plating 
onto Matrigel, and the cells were able to form tube-like structures and branches within 48 
h. However, in HUVECs transduced with siRNA targeting RECK (Fig. 1D, top), the 
tubes formed under the same conditions were significantly shorter and often disconnected 
(Fig. 1D bottom). Shorter tube formation induced by RECK depletion was evident in type 
I collagen 3D gel as well as in the 2D assay (Fig. S1A, B). These findings suggest that 
RECK plays a critical role in physiological angiogenesis.  
 
RECK depletion induces growth arrest and cellular senescence in HUVECs. To 
further characterize the primary effect of RECK depletion in HUVECs, we analyzed 
monolayer cells grown on non-coated plastic dish with EGM-2. HUVECs transduced 
with RECK siRNAs proliferated significantly slower than those transduced with control 
or EGFP siRNA (Fig. 2A). The G0-G1 population in cells transduced with control siRNA 
was 69%, and this figure increased to 85% when the cells were transduced with RECK 
siRNA (Fig. 2B). Similarly, bromodeoxyuridine (BrdU) incorporation was significantly 
reduced by RECK depletion (Fig. 2C). Twelve days after transduction of RECK siRNA, 
we observed a significant level of senescence-associated β-galactosidase (SA-β-gal) 
activity (Fig. 2D) without any evidence of increased cell death as assessed by the 
terminal deoxyribonucleotidyl transferase (TdT)-mediated biotin-16-dUTP nick-end 
labeling (TUNEL) assay (data not shown). These findings suggest that RECK critically 
Miki et al., MCR-09-0351R (second revise) 
 13
supports the proliferation of HUVECs.   
 
Effects of RECK depletion on HUVECs partially depends on MMP-2. Since it was 
previously demonstrated that RECK inhibits the proteolytic activity of a series of 
metalloendopeptidases, including MMP-9 (9), MMP-2 (15), MT1-MMP, 
CD13/aminopeptidase N (APN) (16) and ADAM10 (17), we hypothesized that 
deregulated activation of any of these enzymes induced by RECK depletion would 
contribute to the appearance of phenotypes in HUVECs. siRNAs targeting individual 
genes encoding these enzymes were simultaneously introduced with RECK siRNAs into 
monolayer HUVECs cultured with EGM-2 (Fig. 3A and data not shown). Among tested 
siRNAs, MMP-2 siRNAs significantly antagonized the effect of RECK siRNAs on the 
proliferation of HUVECs (Fig. 3B). In contrast, depletion of MMP-2 without RECK 
depletion did not produce detectable impact on cell proliferation (Figure 3B), suggesting 
that MMP-2 acquires a specific role in the absence of RECK. In the 2D assay, the effect 
of RECK siRNA on tube elongation was significantly rescued by simultaneous inhibition 
of MMP-2 (Fig. 3C), however, the defect in tube branching was not rescued (Fig. 3D). 
The 3D assay results were consistent with the 2D results (Fig. S2). These findings 
suggest that the effects of RECK depletion on vascular formation by HUVECs partially 
depends on MMP-2 and that shorter tube formation correlates with proliferation defect. 
Furthermore, MT1-MMP nor MMP-9 depletion failed to reverse proliferation defects in 
RECK-depleted HUVECs (data not shown); the implication of these findings will be 
discussed later (see below). 
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RECK depletion downregulates the activation of β1-integrin and FAK in an MMP-
2-dependent manner. Next, we addressed whether the involvement of MMP-2 can 
explain why RECK depletion suppresses the proliferation of HUVECs. Since integrins 
are frequent target of anti-angiogenic MMP activities (5), we measured the activity of 
various types of integrins using antibodies that specifically recognize the activated forms 
of integrins by fluorescence-activated cell sorting (FACS). This study revealed that the 
activation of β1-integrin is specifically affected by RECK depletion (Fig. 4A). No 
quantitative differences were detected between cells transduced with RECK siRNA and 
the controls by both FACS and immunoblotting (IB) with antibody reacting with all 
forms of β1-integrin (Fig. S3A). In addition, RECK depletion did not affect β1-integrin 
mRNA expression as assessed by reverse transcription-polymerase chain reaction (RT-
PCR) (Fig. S3B). Furthermore, overexpression of RECK in HT1080 fibrosarcoma cells 
resulted in increased β1-integrin activation (1.7 fold induction) (Fig. 4B) without 
detectable alteration in the total β1-integrin expression level (Fig. S3C, D). These 
findings suggest that RECK stimulates β1-integrin activation in both normal and tumor 
cells.  
 
To determine whether downregulation of β1-integrin activation in HUVECs induced by 
RECK depletion depends on MMP-2, siRNA specifically targeting MMP-2 was 
simultaneously introduced into these cells cultured in EGM-2. This experiment 
demonstrated that the simultaneous inhibition of MMP-2 activity significantly 
antagonizes the effect of RECK depletion on β1-integrin activation in HUVECs (Fig. 4C).  
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To validate the relationship between RECK and integrin signaling, we measured the 
autophosphorylation status of FAK as one of common downstream targets of integrin 
signaling (8). RECK depletion downregulated FAK phosphorylation, and this 
downregulation was significantly antagonized by the simultaneous depletion of MMP-2 
(Fig. 4D).  
  
RECK depletion upregulates p21CIP1 expression in a β1-integrin-dependent manner. 
To prove that downregulation of β1-integrin signaling is responsible for the growth arrest 
and cellular senescence induced by RECK depletion in HUVECs, we treated RECK-
depleted HUVECs with monoclonal antibody that was engineered to specifically 
stimulate β1-integrin activation (19). This experiment resulted in the significant and 
dose-dependent recovery of cell proliferation in RECK-depleted HUVECs in EGM-2 
(Fig. 4E). Further, we observed specific induction of a CDK inhibitor p21CIP1 in HUVECs 
when transduced with RECK siRNA; this effect of RECK siRNA was antagonized by 
treatment with the β1-integrin-stimulating monoclonal antibody (Fig. 4F). In addition, 
simultaneous depletion of MMP-2 antagonized the effect of RECK depletion on p21CIP1 
induction (Fig. 4G). These findings suggest that RECK stimulates FAK activation and 
suppresses p21CIP1 expression by regulating β1-integrin activation in an MMP-2 
dependent manner. Since FAK has been linked to Skp2-independent control of the 
cellular p21CIP1 level (25), we speculated that RECK depletion induces p21CIP1 expression 
by downregulation of β1-integrin signaling followed by inactivation of FAK.  
 
Reck-deficiency downregulates β1-integrin activation in vivo. We next examined the 
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activation status of β1-integrin in vascular endothelial cells in Reck-/- mice to determine 
the relevance of our in vitro findings in vivo. Most of Reck-/- embryos survive up to 
embryonic day (E)10.5 and then die abruptly due to acute hemorrhage in the abdominal 
vessels (15). In E10.0 wild-type embryos, CD31+ vascular endothelial cells abundantly 
express both RECK and β1-integrin. Most CD31+ cells express active β1-integrin in 
wild-type E10.0 embryos; however, in abdominal hemorrhage-free and heart beat-
positive (alive) Reck-/- E10.0 embryos, we detected active β1-integrin signals with 
significantly less frequency although the total β1-integrin signals were at level similar to 
that of the wild-type (Fig 5A, B). These findings suggest that Reck-deficiency 
downregulated β1-integrin activation in the vascular endothelial cells of E10.0 mouse 
embryos.  
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Hyper-vascular tumor cells induce RECK expression in vascular endothelial cells. 
To investigate the role of RECK in pathological angiogenesis, we observed RECK 
expression in mouse-derived CD31+ endothelial cells convoluted in human-derived tumor 
cells (HT1080) that were subcutaneously inoculated into nude mice and grown for 14 d. 
We observed a marked induction of RECK in mouse-derived CD31+ cells in the tumors 
(Fig. 6A). This phenomenon was recapitulated in vitro by co-culturing HUVECs with 
tumor cells on a non-coated dish. Significant induction of RECK under this condition was 
confirmed by IB and the reporter assay for the Reck promoter (Fig. 6B top and S4A). 
Hypoxic condition did not induce RECK expression in HUVECs (data not shown); thus, 
we speculated that tumor cells directly induce the transcription of RECK in vascular 
endothelial cells convoluted in the tumor mass.   
  
A comparison of the RECK-inducing activity exerted by various human tumor-derived 
cell lines revealed that RECK-induction well correlates with the known angiogenic 
activity of each cell line; cell lines derived from hyper-vascular tumors (HT1080: 
fibrosarcoma; SKNSH: neuroblastoma; PC-12: pheochromocytoma) tend to induce 
higher RECK expression in cocultured HUVECs (Fig. 6B, bottom). Moreover, 2 out of 
these 3 tumor cell lines induced a significant level of Reck promoter activation in 
coclutured HUVECs (Fig. S4), suggesting that RECK-induction by tumor cells is at least 
partially dependent on transcriptional control. MCF-7 was exceptional; this line 
significantly transactivated RECK promoter reporter (Fig. 4B), however, only slightly 
upregulated RECK protein expression (Fig. 6B). Interestingly, cell lines with higher 
RECK-inducing activity also tend to express a detectable level of endogenous RECK (Fig. 
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6B bottom), implicating that RECK could be induced in such tumors by an autocrine 
mechanism. However, depletion of endogenously expressed RECK in one of these 
RECK-positive tumor cell lines (HT1080) did not result in detectable changes in cell 
behavior including proliferation, cell death, migration and invasion (data not shown).  
 
To examine the clinical relevance of RECK induction in vascular endothelial cells 
convoluted in tumors in nude mice, we analyzed tumor biopsy tissues from human 
neuroblastomas. As described, these tumors exhibited a high density of vasculature (Fig 
6C, top). We observed weak but significant level of RECK expression in CD31+ vascular 
endothelial cells found within the tumor mass (Fig. 6C, bottom). Similarly, the 
endothelial cells of the larger arteries located close to the tumor mass showed significant 
level of RECK expression. In these arteries, smooth muscle cells also express RECK as 
described previously (15)(Fig. S5). Although not directly addressing whether RECK is 
induced during neuroblastoma development, this study shows that vascular endothelial 
cells at least in human neuroblastomas express a detectable level of RECK.  
 
RECK induction is required for vascular endothelial cells to support tumor growth. 
To determine the biological significance of RECK induction in vascular endothelial cells 
by tumor cells, we employed a tumor angiogenesis model in which human endothelial 
cells (HUVECs) and human fibrosarcoma cells (HT1080) were mixed with Matrigel, and 
allowed to adhere to porous poly-L-lactic acid (PLLA) scaffolds. The complex was 
subcutaneously implanted into SCID mice, and grown for 3 weeks.  
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To distinguish HUVECs from host mouse-derived vascular endothelial cells, we used an 
antibody that specifically reacts with human CD34 (hCD34). HUVECs (CD31+/hCD34+) 
were detected more frequently at the center of the tumors than in the marginal areas (Fig. 
6D, top). The marginal areas were frequently occupied by host mouse-derived 
CD31+/hCD34- cells (Fig. 6D, top). The complex containing HUVECs transduced with 
RECK siRNA produced significantly smaller tumors compared to the controls (Fig. 6D, 
right). Histological analysis revealed a poorer vasculature and a higher degree of necrosis 
at the center of tumors containing HUVECs transduced with RECK siRNA than those in 
the case of tumors containing HUVECs transduced with control siRNA (Fig. 6D, bottom 
and right). These findings suggest that RECK induction in vascular endothelial cells by 
tumor cells is required for supporting tumor growth.  
 
Discussion   
 
In this study, we demonstrated that RECK is induced in vascular endothelial cells by a 
specific angiogenic factor during physiological angiogenesis, and in hyper-vascular 
tumors during pathological angiogenesis. In addition, we characterized the pro-
angiogenic function of RECK, which appeared to at least partially depend on MMP-2 and 
β1-integrin. A similar functional interaction between MMP-2 and β1-integrin signaling 
has been reported in previous analyses of cardiac myocytes (26) and chondrogenic cells 
(27). Thus far, no evidence of a direct interaction between MMP-2 and β1-integrin is 
available. Therefore, we currently speculate that when RECK expression is attenuated in 
vascular endothelial cells, substrates of MMP-2 may participate in the negative regulation 
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of β1-integrin activation as suggested previously (26, 27).  
 
However, in the current study, it was not clarified why simultaneous MMP-2 depletion 
specifically antagonized the effects of RECK depletion on proliferation of HUVECs. It 
was reported that a selective MT1-MMP inhibitor almost completely blocked proMMP-2 
processing in HUVECs (28). However, MT1-MMP depletion was not relevant to MMP-2 
depletion in RECK-depleted HUVECs in our experiment. Since proMMP-2 is not the 
sole substrate of MT1-MMP (29), we speculate that MT1-MMP can exert distinct pro- 
and anti-angiogenic functions even in an MMP-2-independent manner. Thus, we further 
speculate that suppression of the MMP-2-indepdent pro-angiogenic (growth-stimulating) 
function of MT1-MMP masked the rescue effect of MT1-MMP depletion on RECK-
depletion-induced proliferation defects. MMP-9 depletion may have failed to rescue 
rescue the RECK-depletion-induced proliferation defects due to similar reason. Overall, 
these findings indicate bivalent roles of MMP activities in angiogenesis.    
 
Another new insight provided by this study is that proliferation of vascular endothelial 
cells during physiological and pathological angiogenesis is critically controlled by RECK. 
As discussed above, MMP activities provided by vascular endothelial cells can be both 
pro- and anti-angiogenic to the cells themselves. RECK may function to protect 
proliferating vascular endothelial cells from self-produced anti-angiogenic MMP 
activities, as well as from those generated by tumor stromal cells or tumor cells. Specific 
downregulation of RECK in vascular endothelial cells decreased their contribution to 
tumor growth. Conversely, RECK overexpression in experimentally transplanted tumor 
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cells reduced tumor volume by attenuating angiogenesis from host nude mice (15). These 
findings suggest that the effect of RECK on tumor angiogenesis varies depending on the 
location of expression.  
 
RECK expression was undetectable in most of commonly available tumor cell lines by 
conventional IB techniques (9). By applying highly sensitive IB methods, we established 
that PC-12 and HT1080 show the highest endogenous RECK expression among the 
tumor cell lines; however, the level of RECK expressed in these cell lines is far less than 
that in proliferating vascular endothelial cells. In addition, depletion of endogenous 
RECK in HT1080 cells did not show detectable changes in cell behavior. Thus, we 
propose the possibility that RECK principally functions in vascular endothelial cells 
rather than in tumor cells, and supports tumor growth by enhancing angiogenesis rather 
than suppressing it. This statement seems to be contradictory to studies showing positive 
correlation between RECK expression level in tumor tissues and favorable prognosis of 
cancer patients (30, 31). However, virtually none of such studies discriminated RECK 
expression in tumor cells, stromal cells, tumor vessels or other cell lineages composing 
tumors. Furthermore, we still do not know whether RECK actively improves prognosis, 
or the elevated RECK expression is a consequence of less malignant property of tumor 
cells. We recently obtained evidence that RECK promotes self-renewing activity of 
neural stem cells through modulation of Notch signaling (17), and, inversely, suppresses 
proliferation of colorectal cancer cells and mouse embryonic fibroblasts through another 
cellular signaling pathway (Kitajima et al, unpublished). These findings indicate that as 
MMPs are multi-functional, RECK is multi-functional and bivalent especially in growth 




Finally, this study proposed that tumor cells may actively induce RECK expression in the 
surrounding vascular endothelial cells. So far, we did not detect angiopoietin-1 in 
HT1080 cells, suggesting that other factors may mediate RECK induction. Several 
previous reports indicated candidates of mediator such as TIMP-1 or TGF-β (32, 33). 
However, we so far obtained no evidence that these soluble factors could affect RECK 
expression particularly in HUVECs (data not shown). Thus, we are currently examining 
other possible factors controlling RECK expressing in non-cell autonomous manner. 
 
Taken together, our results indicate that tumor propagation via enhanced angiogenesis 
depends on the expression of RECK in proliferating vascular endothelial cells. We 
thereby propose that targeting RECK expressed in tumor vascular endothelial cells could 
be an interesting approach aiming to induce tumor regression.  
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Figure 1. Roles of RECK in vascular development. A, HUVECs grown in the growth 
factor-free culture medium (EBM-2) and then treated with the indicated concentration of 
Angiopoietin-1 or other growth factors (10ng/ml) were analyzed by immunoblotting (IB) 
for the indicated proteins. NT: no treatment. B, Vascular phenotypes in mice of the 
indicated genotype at E10.0. Scale bar: 10 μm. Arrow: an endothelial cell detached from 
the subendothelial layer. C, HUVECs transfected with the indicated siRNA and grown in 
the culture medium supplemented with growth factors (EGM-2) were analyzed by IB 
(left). Two independent clones of siRNA targeting RECK (clone#1 and #2) were used. 
Endopeptidase activities to cleave Mca-Lys-Pro-Leu-Gly-DPA-Ala-Arg-NH2 in the 
culture supernatants were measured (middle). Active per total MMP-2 was determined by 
precipitation with gelatin beads and following immunoblotting using antibody to MMP-2 
(right). Bars are means + standard error (SE) from 3 experiments. D, The RT-PCR 
analysis of HUVECs transfected with the indicated siRNA, trypsinized, suspended for 30 
min, replated on Matrigel, and grown for the indicated period of time (top). Cells at 48 h 
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were analyzed using light microscopy (bottom). Scale bar: 100 μm.  
 
Figure 2. Effect of RECK depletion on the growth of HUVECs. A, Growth curve of 
HUVECs transfected with the indicated siRNA. Culture medium: EGM-2. Plots are 
means ± SE from 3 experiments. B, Cell cycle analysis of HUVECs at 48 h after 
transfection of the indicated siRNA. Data were obtained by FACS analysis. C, BrdU 
incorporation by HUVECs at 48 h after transfection of the indicated siRNA. Bars are 
means + SE from 3 experiments. D, Detection of SA-β-gal activity in HUVECs at 12 
days after transfection of the indicated siRNA.  
 
Figure 3. Effect of RECK depletion on HUVECs partially depends on MMP-2. A, 
Expression of the indicated proteins in HUVECs transfected with the indicated siRNA 
was analyzed by IB. Culture medium: EGM-2. B, Proliferation activity of HUVECs 
transfected with the indicated siRNA. Bars are means + SE from 5 experiments. C, 
HUVECs transfected with the indicated siRNA were grown on Matrigel for 48 h, and 
observed under light microscopy. Scale bars: 100 μm. D, Tube length and number of 
branches were measured. Control siRNA transfected HUVECs were set to 100. Bars are 
means + SE from 5 experiments. *, P value < 0.01.  
 
Figure 4. The β1-integrin-dependent function of RECK. A, The activity of β1-integrin 
signaling in HUVECs transfected with the indicated siRNA was measured by FACS 
using the monoclonal antibody (9EG7) that specifically recognizes active form β1-
integrin on the cell surface (top). Culture medium: EGM-2. The FACS result obtained 
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without adding the primary antibody is also indicated. The quantification of active 
(bottom left) and total (bottom right) β1-integrin is shown. The signal in cells transduced 
with the control siRNA was set to 1.0. Bars are mean + SE from 5 experiments. * P value 
< 0.01. B, HT1080 cells transfected with pCXN2-neo (Vector) or pCXN2-neo-RECK and 
selected were analyzed as in A. Bars are mean + SE from 3 experiments. C, The activity 
of β1-integrin signaling in HUVECs transfected with the indicated combinations of 
siRNA was measured as in panel A. Bars are mean + SE from 3 experiments. *, P value < 
0.01. D, The autophosphorylation status and total amount of FAK were analyzed. E, 
Proliferation of HUVECs transfected with the indicated siRNA cultured in the presence 
of indicated concentrations of antibodies (P4G11). Bars are mean + SE from 5 
experiments. *, P value < 0.01. F, The expression of the indicated proteins in HUVECs 
treated with the indicated siRNAs and antibodies (2 μg/ml) was analyzed. G, The 
expression of the indicated proteins in HUVECs treated with the indicated combinations 
of siRNAs was analyzed.  
 
  
Figure 5. Reck-deficiency downregulates β1-integrin signaling in mouse embryos. A, 
Representative results of immunofluorescence (IF) analysis for the indicated proteins in 
the aorta of the indicated genotype of mice at E10.0 are shown. Total-β1-integrin+/active 
β1-integrin- endothelial cells are indicated by arrows. Scale bar: 10 μm. B, The activity of 
β1-integrin signaling is quantified from observation of 3 embryos of each genotype by 
assessing the frequency of active per total β1-integrin signals. Bars are mean + SE. *, P 
value < 0.01. 
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Figure 6. RECK induction in vascular endothelial cells supports tumor growth. A, IF 
analysis of the host mouse-derived blood vessels developed in a tumor generated by 
subcutaneously introducing 1 x 106 HT1080 cells into a 4 week-old Balb-c nu/nu mouse. 
Antibodies to the indicated proteins were used. Arrows indicate RECK+/CD31+ 
endothelial cells. Scale bars: 20 μm. B, Induction of RECK in HUVECs cocultured with 
HT1080 cells. 5 x 104 HUVECs were cocultured with 2.5 (+), 5.0 (++) or 10 (+++) x 104 
HT1080 cells for 24 h (upper, top). Culture medium: Dulbecco’s Modified Eagle’s 
medium supplemented with 10% fetal calf serum. Endogenous RECK expression in the 
same number of HT1080 cells is also examined (upper, bottom). Induction of RECK in 5 
x 104 HUVECs cocultured with the indicated tumor cell lines (5 x 104) (lower, top). 
Endogenous RECK expression in the same number of tumor cells is also examined 
(lower, bottom). C, A section from a human neuroblastoma obtained by biopsy was 
stained with hematoxylin and eosin (HE) (top). Scale bar: 100 μm. RECK expression in a 
CD31+ blood vessel found in the tumor mass was detected by IF (bottom). Scale bar: 10 
μm. D, HT1080 cells and HUVECs were loaded into PLLA scaffolds and grown in SCID 
mice for 3 weeks. Sections of different parts of a tumor (marginal and center) were 
stained for the indicated proteins (top). CD31+/hCD34- cells: arrow heads; 
CD31+/hCD34+ cells: arrows. HT1080 cells and HUVECs transfected with the indicated 
siRNA were loaded into PLLA scaffolds and grown in SCID mice for 3 weeks. Tumor 
sections were stained for the indicated protein and DAPI (4',6-diamino-2-phenylindole) 
or by HE (bottom). Scale bar: 100 μm. Density of hCD34+ endothelial cells (per x 40 
magnification field, 10 fields were observed) (right, top) and tumor weights (right, 
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bottom) were measured. Bars are means + SE from 5 independent tumors. *, P value < 
0.01; *, P value < 0.05. 
 






